GMD has released its FY27 guidance for a "stand-alone" Genesis, given the proposed merger is targeted for completion in Nov'26. Overall, production and capex guidance are in-line with CitiE and VA consensus expectations; however, AISC of A$2,750–3,050/oz was higher than expectations (+10% vs CitiE, +5% vs VA consensus). The JunQ was mostly pre-released (see note), with AISC being the relevant new data, landing 4% ahead of CitiE and 6% ahead of VA consensus. Unaudited FY26 underlying NPAT stands at A$540–550 ...

Action | 27 Jul 2026 21:59:37 ET │ 15 pages Grupo Mexico (GMEXICOB.MX) Model Update: Incorporating Saavi Energia; Maintain Neutral and Raise TP to P$220/sh CITI'S TAKE | Estimates | 2025A | 2026E | 2027E | 2028E | Q126A | Q226A | Q326E | Q426E | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | Sales (US$M) | 18,181 | 22,790 | 23,250 | 21,355 | 5,565 | 5,718 | 5,692 | 5,815 | | EBITDA adj (US$M) | 9,956 | 13,963 | 14,046 | 12,591 | 3,314 | 3,536 | 3,505 | 3,608 | | EBITDA margin adj (%) | 54.8 | 61. ...

Flash | 27 Jul 2026 21:39:24 ET │ 12 pages OMA Airports (OMAB.MX) 2Q26 Review: In line; momentum building into 2H26 CITI'S TAKE OMAB posted an Adj EBITDA at P$2.7bn, in line with consensus. YTD traffic dynamics seems supportive of our 4.5% YoY forecast for 2026 FY, which implies an acceleration going into 2H26. OMAB remains the better balanced Mexican airport from a valuation and traffic momentum perspective. We reiterate our Buy rating. Adj. EBITDA in line with Citi and consensus — OMA reported total reven ...

Flash | 27 Jul 2026 21:24:01 ET │ 12 pages Brixmor Property Group (BRX.N) No Surprises, Just Results: BRX Posts In-Line Quarter, Lifts Outlook CITI'S TAKE BRX reported 2Q26 FFO of $0.58, which was in-line with consensus but +1c (+1.75%) above Citi. The 2026 FFO guidance range was increased by +0.5c at the midpoint and is now in line with the Street at $2.36. The continued demand tailwind amid minimal new supply supported underlying strength in tenant credit and blended rent spreads of +19.1% (- 790 bps vs. ...

Flash | Kilroy Realty Corp (KRC.N) KRC Beats & Reaffirms Guidance; Thoughts on 2Q26 Earnings CITI'S TAKE KRC reported 2Q26 FFO of 92c, +2c (~2%) above CitiE at 90c and +3c (~3%) above the Street/FactSet at 89c, and reaffirmed 2026 FFO guidance at the current range of $3.49 – $3.63, which at the midpoint is in line with CitiE and the Street (FactSet) at $3.56. Guidance assumptions largely remain unchanged except for total development spend (revised to +/- $150M from $150M-$200M). Fundamentals softened sequen ...

Flash | 27 Jul 2026 20:59:08 ET │ 12 pages Liverpool (LIVEPOLC1.MX) 2Q26 Review: Slight Miss. Weak Retail Trends Persist; Nordstrom Supports Below the Line CITI'S TAKE Liverpool delivered a soft 2Q26, with EBITDA 4%/2% below CitiE/consensus as weak retail trends continued to weigh on operating performance. The main lowlight was Suburbia, with SSS declining 6.4%YoY amid subdued demand and lower clearance activity, reflecting management's focus on profitability over promotional sales. While this strategy, com ...

Flash | Neutral 27 Jul 2026 20:55:24 ET │ 11 pages IGO Ltd (IGO.AX) 4Q26 Results: Greenbushes Improves, CGP3 Near to Restart but Costs Ahead of Expectations CITI'S TAKE Underlying EBITDA of A$118m was broadly flat QoQ, although below our A$137m estimate as higher production was offset by higher costs. The quarter supports our view that the worst is likely behind operationally at Greenbushes: spodumene production of 387kt was 3% above CitiE, sales were 4% ahead, and realised pricing of US$2,286/t was 3% abov ...

Flash | 27 Jul 2026 20:05:34 ET │ 10 pages Lexicon Pharmaceuticals (LXRX.O) Enrollment Completion in Ph3 SONATA-HCM Sets Up Potentially Transformative Stock Catalyst in 1Q27 CITI'S TAKE The Ph3 SONATA-HCM trial completed enrollment on schedule, with topline still expected 1Q27. The study substantially exceeded the 500- patient target, boosting statistical power to detect a placebo-adjusted KCCQ-CSS improvement in the 4–5 point range, consistent with the historically accepted clinical meaningfulness threshol ...

Flash | 27 Jul 2026 20:05:48 ET │ 13 pages Welltower (WELL.N) All Is Well; WELL Beats and Raises CITI'S TAKE WELL raised 2026 guidance for the second time this year +1.9% to $6.40 at the midpoint (range: $6.36-$6.44), which is +1.6% ahead of the Street (FactSet) at $6.30 and +1.4% ahead of Citi at $6.31. Roughly two-thirds of the guidance raise was driven by investment activity, with $15.5B of pro- rata gross investments, inclusive of newer-vintage SHOP communities at ~75% occupancy with embedded upside. Op ...

Flash | 27 Jul 2026 20:12:10 ET │ 11 pages Vivo (VIVT3.SA) 2Q26 Review: Lukewarm CITI'S TAKE Vivo delivered mixed 2Q26 #S with EBITDA (ex-others) exceeding our number by 3% on lower opex, tough largely in-line after accounting for higher leasing and capex, and with recurring FCFE of R$2.2bn (or R$1.8bn ex-asset sale) falling short of our estimates. Topline exceeded our number by 1%, driven by stronger handset sales (+28% y/y), while MSR +6.6% and fixed revenues came largely in-line. Moreover, gross margin f ...